Research News
View articles by month and year
-
Is Switching Hormonal Therapies Better Than Taking Only One?
Research suggests that taking tamoxifen for 2 to 3 years and then switching to an aromatase inhibitor might be better than taking only tamoxifen or only an aromatase inhibitor for 5 years to reduce recurrence risk and improve overall survival.
-
Tamoxifen Reduces Recurrence Risk for More Than 10 Years
Research has confirmed that tamoxifen reduces breast cancer recurrence risk during the standard 5 years of treatment and that recurrence risk stays lower during the next 5 years after tamoxifen treatment ends.
-
Zometa Plus Hormonal Therapy Reduces Recurrence Risk
A study has found that Zometa and hormonal therapy after surgery could reduce the risk of the cancer coming back in premenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer better than hormonal therapy alone.
-
Chemo, Hormonal Therapy May Increase Risk of Falling
Research suggests that women who get chemotherapy or hormonal therapy to treat early-stage breast cancer are more likely to fall than women the same age who don't get those treatments.
-
Hormonal Therapy for Breast Cancer May Boost Lung Cancer Survival
A large study found that women treated with hormonal therapy for breast cancer were 87% less likely to die from lung cancer compared to the average person's risk of dying from lung cancer.
-
Arimidex and Aromasin Equally Good at Reducing Recurrence Risk
A new study shows that Arimidex and Aromasin are equally good at reducing the risk of recurrence in postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.
-
Aromatase Inhibitors Increase Risk of Heart Problems
Women diagnosed with early-stage, hormone-receptor-positive breast cancer who got 5 years of an aromatase inhibitor seem to be more likely to have heart problems compared to women who got 5 years of tamoxifen.
-
Radiation, Tamoxifen After DCIS Surgery Reduces Recurrence Risk
Research shows that radiation therapy and hormonal therapy after surgery for DCIS reduces the risk of being diagnosed with either another DCIS or invasive breast cancer in the future.
-
Arimidex Still Better Than Tamoxifen After Surgery to Reduce Recurrence Risk
After 10 years of follow-up, research shows that 5 years of Arimidex is better at reducing the risk of hormone-receptor-positive breast cancer recurrence than 5 years of tamoxifen.
-
New Guidelines Prefer Aromatase Inhibitors Over Tamoxifen
The American Society of Clinical Oncology has issued new guidelines on taking hormonal therapy medicines after breast cancer surgery.
